Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of
pulmonary arterial hypertension
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Dear member of the investment community
Actelion announced today that the United States Food and Drug Administration
(FDA) has approved the use of the orally active, selective IP prostacyclin
receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial
hypertension (PAH).
An investor conference call & webcast will be held to discuss the approval at
14:00hrs on 05 January 2016.
Date/Time:
05 January 2016 14:00hrs - 15:00hrs Basel (CET)
13:00hrs - 14:00hrs UK (GMT)
8:00 a.m. - 9:00 a.m. US (EST)
Conference Call and Webcast
Participants will find dial-in information and a link to the webcast on the
Actelion website www.actelion.com at least 24hrs ahead of when the conference is
due to start.
Webcast Replay:
The archived Investor Webcast will be available for replay through
www.actelion.com approximately 60 minutes after the call has ended.
Press release.PDF:
http://hugin.info/131801/R/1975273/722851.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
[HUG#1975273]
Unternehmensinformation / Kurzprofil:
Datum: 22.12.2015 - 07:20 Uhr
Sprache: Deutsch
News-ID 441169
Anzahl Zeichen: 2051
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 462 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
